Aardvark Therapeutics (AARD) Cash & Current Investments (2024 - 2026)

Aardvark Therapeutics has reported Cash & Current Investments for 3 years, with the latest figure at $120.0 million in Q1 2026.

• Quarterly Cash & Current Investments fell 56.54% year-over-year to $120.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $120.0 million (down 56.54% YoY) and the FY2025 annual result came in at $110.0 million, up 49.37% from the prior year.
• Cash & Current Investments climbed to $120.0 million in Q1 2026 per AARD's latest filing, from $110.0 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $276.1 million in Q1 2025 and troughed at $73.7 million in Q4 2024.
• A 3-year average of $175.1 million and a median of $166.7 million in 2025 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2025 and 2026: Cash & Current Investments surged 49.37% in 2025, then tumbled 56.54% in 2026.
• Over 3 years, Cash & Current Investments stood at $73.7 million in 2024, then soared by 49.37% to $110.0 million in 2025, then gained by 9.03% to $120.0 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $120.0 million, $110.0 million, and $213.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.